NSE: SYNGENE · 28 October 2026
- Syngene International has risen 12.55% over 2 trading sessions; today's move is +10.60%.
- Syngene International reported a sequential revenue increase of 13% to ₹833 crore for the quarter ended September 30, 2026, compared to ₹736 crore in the preceding quarter. Operating EBITDA margin improved by 6 percentage points to 18%, while profit after tax before exceptional items stood at ₹38 crore.
- Trading volume was 43.07 times the 20-day average daily volume.
Syngene International share price: 12.55% rise over 2 trading sessions
Syngene International Ltd. (SYNGENE) shares rose 10.60% during the trading session, opening at ₹385.50 and moving within a day's range of ₹374.55 to ₹418.45 before settling at ₹405.00.
While the broader Nifty benchmark dipped 0.22%, the sector benchmark Nifty Pharma advanced 1.04%.
The price movement coincides with the company's Q2 FY27 financial results released on October 27, 2026, which reported sequential revenue growth of 13% quarter-on-quarter to ₹833 crore and an operating EBITDA margin of 18%, alongside a signed manufacturing agreement for its Bayview biologics facility.
3.26 crore shares traded by 28 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 7.58 lakh shares (43.07 times). The five-day average daily volume was 6.78 lakh shares. Separately, the NSE report for 27 October 2026 showed 4.84 lakh shares delivered, representing 54.61% of that day’s traded volume. The same report recorded 54,734 trades.
The stock's sharp upward move and elevated volume directly followed the release of Q2 FY27 financial results showing sequential revenue growth and improved operating margins, alongside strategic contract wins.
Latest Company Developments
Syngene International reported a sequential revenue increase of 13% to ₹833 crore for the quarter ended September 30, 2026, compared to ₹736 crore in the preceding quarter. Operating EBITDA margin improved by 6 percentage points to 18%, while profit after tax before exceptional items stood at ₹38 crore.
Demonstrates sequential business recovery and operational margin expansion led by traction in the CDMO business.
The company announced it has signed its first manufacturing agreement for the Bayview biologics facility in the U.S. with a large pharmaceutical customer. Process development will begin in India this fiscal year, with drug substance manufacturing at Bayview scheduled to start next year.
Marks an important operational milestone in expanding the company's integrated India-U.S. dual-continent supply capabilities.
Syngene announced multiple leadership updates, including Chief Financial Officer Deepak Jain's decision to move on for personal reasons, with a transition timeline through the third quarter. Additionally, Ajay Tandon, Head of Strategy and Corporate Development, submitted his resignation effective October 30, 2026.
Key executive changes require careful monitoring for operational continuity during ongoing business restructuring.
a press release dated October 27, 2026, titled "Syngene reports sequential revenue growth of 13% in Q2 FY27; Operating EBITDA margin improves by 6 percentage points".
Syngene International Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 27.10% on 30 September 2026. This compares with 25.78% on 30 June 2026, a change of +1.32 percentage points.
The filing reported 28 MF/UTI holders.
What to Watch Next
- Execution of the newly signed Bayview biologics facility manufacturing agreement
- Progress on cost-optimization initiatives and non-manpower expense controls
- Transition timeline and replacement announcements for departing senior management
- Customer traction and pipeline conversion in the CDMO and integrated drug discovery segments
Other Dated Coverage
More Syngene International news and dated analysis →
Frequently Asked Questions
What is the latest Syngene International company news?
Syngene International reported a sequential revenue increase of 13% to ₹833 crore for the quarter ended September 30, 2026, compared to ₹736 crore in the preceding quarter. Operating EBITDA margin improved by 6 percentage points to 18%, while profit after tax before exceptional items stood at ₹38 crore.
How strong was Syngene International’s trading volume?
3.26 crore shares traded, 43.07 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.